Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res January 1 2019 7 (1) 1-1;

Meeting Report

  • Meeting Report
    Translating Science into Survival: Report on the Fourth International Cancer Immunotherapy Conference
    Mustafa Diken, Srivani Ravoori and Arthur N. Brodsky
    Cancer Immunol Res January 1 2019 7 (1) 2-5; DOI:10.1158/2326-6066.CIR-18-0866

Cancer Immunology Miniature

  • Cancer Immunology Miniature
    Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
    Emma C. de Moel, Elisa A. Rozeman, Ellen H. Kapiteijn, Els M.E. Verdegaal, Annette Grummels, Jaap A. Bakker, Tom W.J. Huizinga, John B. Haanen, René E.M. Toes and Diane van der Woude
    Cancer Immunol Res January 1 2019 7 (1) 6-11; DOI:10.1158/2326-6066.CIR-18-0245

    Ipilimumab induced autoantibodies in a fifth of melanoma patients. Patients who developed autoantibodies, especially thyroid autoantibodies, experienced more irAEs and had a survival and response benefit, suggesting that breaking of B-cell tolerance could indicate therapy toxicity and efficacy.

Research Articles

  • Research Articles
    Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome
    Raffaella Vescovi, Matilde Monti, Daniele Moratto, Lucia Paolini, Francesca Consoli, Luisa Benerini, Laura Melocchi, Stefano Calza, Mariella Chiudinelli, Giulio Rossi, Mattia Bugatti, Michele Maio, Ester Fonsatti, Camillo Farisoglio, Michele Simbolo, Camillo Almici, Rosanna Verardi, Aldo Scarpa, Paolo Bergese, Ausilia Manganoni, Fabio Facchetti and William Vermi
    Cancer Immunol Res January 1 2019 7 (1) 12-28; DOI:10.1158/2326-6066.CIR-18-0141

    Plasmacytoid dendritic cells (PDCs) can regulate anti-cancer immune responses. Factors in the melanoma secretome drive the PDC compartment to collapse during disease progression, and rescue of PDCs could aid existing spontaneous and drug-induced adaptive immune responses.

  • Research Articles
    Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation
    Derek J. Theisen, Stephen T. Ferris, Carlos G. Briseño, Nicole Kretzer, Arifumi Iwata, Kenneth M. Murphy and Theresa L. Murphy
    Cancer Immunol Res January 1 2019 7 (1) 29-39; DOI:10.1158/2326-6066.CIR-18-0138

    In addition to stabilizing cDC1 dendritic cell lineage commitment, BATF3 controls a set of genes required for cDC1 cells to promote tumor rejection. These BATF3-controlled genes, which are independent of cross-presentation, may be targets in the development of immunotherapies.

  • Research Articles
    Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens
    Aaron M. Miller, Milad Bahmanof, Dietmar Zehn, Ezra E.W. Cohen and Stephen P. Schoenberger
    Cancer Immunol Res January 1 2019 7 (1) 40-49; DOI:10.1158/2326-6066.CIR-18-0371

    Adoptive cellular therapy (ACT) with a low-affinity T-cell receptor (TCR) that recognizes a self-antigen yields antitumor cytotoxicity but not autoimmune damage. A better understanding of TCR affinity could ultimately minimize autoimmunity while increasing ACT therapeutic efficacy.

  • Research Articles
    High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions
    Dylan T. Blaha, Scott D. Anderson, Daniel M. Yoakum, Marlies V. Hager, Yuanyuan Zha, Thomas F. Gajewski and David M. Kranz
    Cancer Immunol Res January 1 2019 7 (1) 50-61; DOI:10.1158/2326-6066.CIR-18-0395

    Using a rapid, high-throughput method, peptide/HLA thermal stability was determined for a variety of peptides and peptide variants. This approach allows for predicting neoantigens that can best serve as targets for a robust T-cell response against cancer.

  • Research Articles
    Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells
    Juliane Liepe, John Sidney, Felix K.M. Lorenz, Alessandro Sette and Michele Mishto
    Cancer Immunol Res January 1 2019 7 (1) 62-76; DOI:10.1158/2326-6066.CIR-18-0424

    Unconventional spliced peptides can be presented by cancer cells. This survey of peptide characteristics in the immunopeptidome of colon and breast carcinoma cell lines may help to predict and identify an unforeseen pool of antigenic targets for immunotherapy.

  • Research Articles | AuthorChoice
    Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
    Sabrina A. Hogan, Anaïs Courtier, Phil F. Cheng, Nicoletta F. Jaberg-Bentele, Simone M. Goldinger, Manuarii Manuel, Solène Perez, Nadia Plantier, Jean-François Mouret, Thi Dan Linh Nguyen-Kim, Marieke I.G. Raaijmakers, Pia Kvistborg, Nicolas Pasqual, John B.A.G. Haanen, Reinhard Dummer and Mitchell P. Levesque
    Cancer Immunol Res January 1 2019 7 (1) 77-85; DOI:10.1158/2326-6066.CIR-18-0136

    Analysis of TCR repertoire clonality in blood samples collected from patients with melanoma before treatment may predict their eventual response to anti-PD1 and anti-CTLA4 therapy. Such a biomarker could help clinicians refine treatment courses for melanoma patients.

  • Research Articles
    Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types
    Allison R. Greenplate, Daniel D. McClanahan, Brian K. Oberholtzer, Deon B. Doxie, Caroline E. Roe, Kirsten E. Diggins, Nalin Leelatian, Megan L. Rasmussen, Mark C. Kelley, Vivian Gama, Peter J. Siska, Jeffrey C. Rathmell, P. Brent Ferrell, Douglas B. Johnson and Jonathan M. Irish
    Cancer Immunol Res January 1 2019 7 (1) 86-99; DOI:10.1158/2326-6066.CIR-17-0692

    An analysis toolkit was developed for characterizing immunological changes over time in clinical samples. Use of this toolkit revealed the presence of a double-negative T-cell subset in melanoma, glioblastoma, and renal cell carcinoma but not in healthy tissues.

  • Research Articles
    Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
    Susanne H. Baumeister, Joana Murad, Lillian Werner, Heather Daley, Helene Trebeden-Negre, Joanina K. Gicobi, Adam Schmucker, Jake Reder, Charles L. Sentman, David E. Gilham, Frédéric F. Lehmann, Ilene Galinsky, Heidi DiPietro, Kristen Cummings, Nikhil C. Munshi, Richard M. Stone, Donna S. Neuberg, Robert Soiffer, Glenn Dranoff, Jerome Ritz and Sarah Nikiforow
    Cancer Immunol Res January 1 2019 7 (1) 100-112; DOI:10.1158/2326-6066.CIR-18-0307

    NKG2D-CAR T-cell therapy is safe and feasible. Infused cells were transiently detected and exhibited in vitro responses to autologous tumors. However, objective responses to low doses were only seen in lymphodepleted patients, warranting studies to improve efficacy.

  • Research Articles
    Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid
    Natascha Stergiou, Nikola Gaidzik, Anne-Sophie Heimes, Sarah Dietzen, Pol Besenius, Jörg Jäkel, Walburgis Brenner, Marcus Schmidt, Horst Kunz and Edgar Schmitt
    Cancer Immunol Res January 1 2019 7 (1) 113-122; DOI:10.1158/2326-6066.CIR-18-0256

    Tumor-associated MUC1 is a target for the development of breast cancer vaccines due to its tumor-specific overexpression and aberrant glycosylation. Immunization with synthetically produced tumor-associated MUC1 glycopeptides conjugated to tetanus toxoid resulted in reduced tumor burden in mice.

  • Research Articles | AuthorChoice
    Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells
    Yichen Chen, Da Ma, Xi Wang, Juan Fang, Xiangqi Liu, Jingjing Song, Xinye Li, Xianyue Ren, Qiusheng Li, Qunxing Li, Shuqiong Wen, Liqun Luo, Juan Xia, Jun Cui, Gucheng Zeng, Lieping Chen, Bin Cheng and Zhi Wang
    Cancer Immunol Res January 1 2019 7 (1) 123-135; DOI:10.1158/2326-6066.CIR-18-0124

    T-cell numbers and effector functions are diminished by calnexin, an ER chaperone protein, possibly through PD-1 upregulation, in OSCC patients and in a mouse melanoma model. These results suggest calnexin could be targeted to improve immunotherapy responses.

  • Research Articles | AuthorChoice
    PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
    Ling Ding, Xi Chen, Xiaqing Xu, Yuli Qian, Guikai Liang, Fengqi Yao, Zhangting Yao, Honghai Wu, Jieqiong Zhang, Qiaojun He and Bo Yang
    Cancer Immunol Res January 1 2019 7 (1) 136-149; DOI:10.1158/2326-6066.CIR-18-0071

    PARP1-mediated poly(ADP-ribosyl)ation of STAT3 drives its dephosphorylation, leading to the inhibition of PD-L1 transcription across multiple cancer types. In patients, PARP1 and PD-L1 expression are inversely correlated. These data highlight a conserved regulatory mechanism for PD-L1 expression.

  • Research Articles
    PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer
    Sandra Heskamp, Peter J. Wierstra, Janneke D.M. Molkenboer-Kuenen, Gerwin W. Sandker, Soley Thordardottir, Jeannette Cany, Daniel Olive, Johan Bussink, Otto C. Boerman, Harry Dolstra, Erik H.J.G. Aarntzen and Willemijn A. Hobo
    Cancer Immunol Res January 1 2019 7 (1) 150-161; DOI:10.1158/2326-6066.CIR-18-0280

    PD-L1 microSPECT/CT is a technique to detect PD-L1 expression in syngeneic murine models and humanized mice, allowing the monitoring of therapy-induced changes in tumor PD-L1 expression. In the future, this technique could enable patient selection for PD-1/PD-L1-targeted therapies.

Correction

  • Correction | Free Article
    Correction: Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer
    Cancer Immunol Res January 1 2019 7 (1) 162-162; DOI:10.1158/2326-6066.CIR-18-0889

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers
    Acknowledgment to Reviewers
    Cancer Immunol Res January 1 2019 7 (1) 163-165; DOI:10.1158/2326-6066.CIR-7-1-Reviewers

Back to top
PreviousNext
Cancer Immunology Research: 7 (1)
January 2019
Volume 7, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Meeting Report
  • Cancer Immunology Miniature
  • Research Articles
  • Correction
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement